Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

305.55DKK
23 May 2018
Change (% chg)

kr.-2.75 (-0.89%)
Prev Close
kr.308.30
Open
kr.306.65
Day's High
kr.307.00
Day's Low
kr.302.70
Volume
2,327,882
Avg. Vol
3,067,706
52-wk High
kr.354.80
52-wk Low
kr.260.20

Chart for

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.51
Market Cap(Mil.): kr.610,749.88
Shares Outstanding(Mil.): 1,962.56
Dividend: 3.00
Yield (%): 2.44

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 20.21 30.95 32.75
EPS (TTM): 15.40 -- --
ROI: 76.65 14.84 14.38
ROE: 84.84 16.34 16.07

BRIEF-Epigen Biosciences Says Enters Collaboration Agreement With Novo Nordisk A/S

* EPIGEN BIOSCIENCES SAYS ENTERS COLLABORATION TO LICENSE ITS LPA1 RECEPTOR SMALL MOLECULE PROGRAM TO NOVO NORDISK A/S FOR UP TO USD 200 MILLION

May 23 2018

Factbox: Company deals at risk from U.S. sanctions on Iran

French gas and power group Engie , Polish gas firm PGNiG and German lender DZ Bank were the latest companies on Friday to say that their business dealings with Iran would be affected by the re-imposition of U.S. sanctions.

May 18 2018

Factbox: Company deals at risk from U.S. sanctions on Iran

A.P. Moller-Maersk, the world's biggest container shipper, said on Thursday it planned to shut down operations in Iran.

May 17 2018

Factbox: Iran's deals with foreign firms since easing of sanctions in 2015

President Donald Trump on Tuesday pulled the United States out of the 2015 international nuclear deal with Iran, raising the risk of conflict in the Middle East, upsetting European allies and casting uncertainty over global oil supplies.

May 09 2018

BRIEF-Novo Nordisk Says Initiated New Share Repurchase Programme For Up To Dkk 2.7 Billion

* AS PART OF UPTO DKK 14 BILLION 2018 SHARE REPURCHASE PROGRAMME, CO INITIATED NEW SHARE REPURCHASE PROGRAMME FOR AN AMOUNT OF UP TO DKK 2.7 BILLION

May 04 2018

BRIEF-Novo Nordisk A/S purchases B Shares worth Dkk 1,038 Mln from Novo Holdings A/S under 2018 share repurchase programme

* NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 1,038 MILLION FROM NOVO HOLDINGS A/S UNDER THE 2018 SHARE REPURCHASE PROGRAMME

May 04 2018

Novo Nordisk upbeat on new diabetes drug as profit tops forecast

COPENHAGEN Novo Nordisk , the world's biggest maker of diabetes drugs, reported a smaller than expected fall in first-quarter profit and nudged up its full-year forecast as sales of new medicines helped to soften the hit from a weaker U.S. dollar.

May 02 2018

UPDATE 2-Novo Nordisk upbeat on new diabetes drug as profit tops forecast

* U.S. legislation puts pressure on 2019 sales (Adds CEO quotes, share price)

May 02 2018

BRIEF-Novo Nordisk CEO: New Ozempic Drug To Reach At Least DKK 1 Billion Sales In 2018

May 2 NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN SAID AT CALL AFTER Q1 EARNINGS:

May 02 2018

Drugmaker Novo Nordisk beats Q1 profit expectations, nudges up 2018 outlook

COPENHAGEN, May 2 Denmark's Novo Nordisk , the world's biggest maker of diabetes drugs, posted a posted first-quarter operating profit above expectations on Wednesday and lifted the lower end of its 2018 sales and profit outlook.

May 02 2018

Earnings vs. Estimates